These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 39136056)

  • 1. Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver.
    Wilson RB; Chen YJ; Zhang R; Maini S; Andrews TS; Wang R; Borradaile NM
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G608-G622. PubMed ID: 39136056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
    Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
    Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice.
    Hetherington AM; Sawyez CG; Sutherland BG; Robson DL; Arya R; Kelly K; Jacobs RL; Borradaile NM
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27613825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression.
    Wu LF; Zhou ZJ; Zeng YH; Yang SL; Zhang QY
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G485-G498. PubMed ID: 39259911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver matrin-3 protects mice against hepatic steatosis and stress response via constitutive androstane receptor.
    Cheng X; Baki VB; Moran M; Liu B; Yu J; Zhao M; Li Q; Riethoven JJ; Gurumurth CB; Harris EN; Sun X
    Mol Metab; 2024 Aug; 86():101977. PubMed ID: 38936659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elongation factor 1A1 regulates metabolic substrate preference in mammalian cells.
    Wilson RB; Kozlov AM; Hatam Tehrani H; Twumasi-Ankrah JS; Chen YJ; Borrelli MJ; Sawyez CG; Maini S; Shepherd TG; Cumming RC; Betts DH; Borradaile NM
    J Biol Chem; 2024 Mar; 300(3):105684. PubMed ID: 38272231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
    Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
    United European Gastroenterol J; 2024 Oct; 12(8):1056-1068. PubMed ID: 38894596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte-specific Epidermal Growth Factor Receptor Deletion Promotes Fibrosis but has no Effect on Steatosis in Fast-food Diet Model of Metabolic Dysfunction-associated Steatotic Liver Disease.
    Bano S; Copeland MA; Stoops JW; Orr A; Jain S; Paranjpe S; Mooli RGR; Ramakrishnan SK; Locker J; Mars WM; Michalopoulos GK; Bhushan B
    Cell Mol Gastroenterol Hepatol; 2024; 18(4):101380. PubMed ID: 39038606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis.
    Gunn PJ; Pramfalk C; Millar V; Cornfield T; Hutchinson M; Johnson EM; Nagarajan SR; Troncoso-Rey P; Mithen RF; Pinnick KE; Traka MH; Green CJ; Hodson L
    Physiol Rep; 2020 Jul; 8(13):e14482. PubMed ID: 32643289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc finger BED-type containing 3 promotes hepatic steatosis by interacting with polypyrimidine tract-binding protein 1.
    Wu Y; Yang M; Wu SB; Luo PQ; Zhang C; Ruan CS; Cui W; Zhao QR; Chen LX; Meng JJ; Song Q; Zhang WJ; Pei QQ; Li F; Zeng T; Du HX; Xu LX; Zhang W; Zhang XX; Luo XH
    Diabetologia; 2024 Oct; 67(10):2346-2366. PubMed ID: 39037604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.
    Chen X; Peng R; Peng D; Liu D; Li R
    J Transl Med; 2024 Jul; 22(1):701. PubMed ID: 39075482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomy.
    Chen S; Zeng Q; Cai X; Xue J; Yin G; Song P; Tang L; Klein C; Tacke F; Guillot A; Liu H
    Int J Biol Sci; 2024; 20(11):4438-4457. PubMed ID: 39247824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids.
    Correia de Sousa M; Delangre E; Berthou F; El Harane S; Maeder C; Fournier M; Krause KH; Gjorgjieva M; Foti M
    JHEP Rep; 2024 Sep; 6(9):101126. PubMed ID: 39263327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.
    Fernández-Tussy P; Cardelo MP; Zhang H; Sun J; Price NL; Boutagy NE; Goedeke L; Cadena-Sandoval M; Xirouchaki CE; Brown W; Yang X; Pastor-Rojo O; Haeusler RA; Bennett AM; Tiganis T; Suárez Y; Fernández-Hernando C
    JCI Insight; 2024 Aug; 9(19):. PubMed ID: 39190492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression.
    Jun JH; Du K; Dutta RK; Maeso-Diaz R; Oh SH; Wang L; Gao G; Ferreira A; Hill J; Pullen SS; Diehl AM
    J Clin Invest; 2024 Aug; 134(19):. PubMed ID: 39190624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex- and age-associated factors drive the pathophysiology of MASLD.
    Yadav AK; MacNeill JJ; Krylov A; Ashrafi N; Mimi RA; Saxena R; Liu S; Graham SF; Wan J; Morral N
    Hepatol Commun; 2024 Sep; 8(9):. PubMed ID: 39185904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.